Towards a Brucella vaccine for humans.
暂无分享,去创建一个
[1] I. F. Huddleson,et al. The Pathogenicity of the Species of the Genus Brucella for Monkeys. , 1929 .
[2] S. Elberg,et al. Respiratory pathogenicity of Brucella. , 1948, The Journal of infectious diseases.
[3] A. Braude,et al. Studies in the pathology and pathogenesis of experimental brucellosis. I. A comparison of the pathogenicity of Brucella abortus, Brucella melitensis, and Brucella suis for guinea pigs. , 1951, The Journal of infectious diseases.
[4] S. Elberg,et al. Immunization against brucella infection. I. Isolation and characterization of a streptomycin-dependent mutant. , 1953, Journal of bacteriology.
[5] K. F. Meyer,et al. IMMUNIZATION AGAINST BRUCELLA INFECTION II , 1953, Journal of bacteriology.
[6] Vershilova Pa. The use of live vaccine for vaccination of human beings against brucellosis in the USSR. , 1961 .
[7] P. Vershilova. The use of live vaccine for vaccination of human beings against brucellosis in the USSR. , 1961, Bulletin of the World Health Organization.
[8] James W. Hall,et al. Immunization with viable Brucella organisms. Results of a safety test in humans. , 1962, Bulletin of the World Health Organization.
[9] G. Rasooly,et al. Immunization against Brucella with killed vaccines. Immunizing activity in mice of Brucella cell walls and of fractions derived from them. , 1966, Israel journal of medical sciences.
[10] R. Sidwell,et al. Experimental studies with four species of Brucella in selected wildlife, laboratory, and domestic animals. , 1967, The American journal of tropical medicine and hygiene.
[11] G. Rasooly,et al. Immunization against Brucella with killed baccines. 3. Experiments in mice. , 1968, Israel journal of medical sciences.
[12] D. Percy,et al. Experimental Brucella canis infection in the monkey (Macaca arctoides). , 1972, Canadian journal of comparative medicine : Revue canadienne de medecine comparee.
[13] G. Renoux,et al. Phenol-water fractions from smooth Brucella abortus and Brucella melitensis: immunochemical analysis and biologic behavior. , 1973, The Journal of infectious diseases.
[14] J. Roux,et al. Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances , 1976, Infection and immunity.
[15] A. Kaufmann,et al. AIRBORNE SPREAD OF BRUCELLOSIS , 1980, Annals of the New York Academy of Sciences.
[16] M. Hogarth,et al. In vivo and in vitro effects of monoclonal antibody to Ly antigens on immunity to infection. , 1982, Cellular immunology.
[17] Meador Vp,et al. Experimentally induced Brucella abortus infection in pregnant goats. , 1986 .
[18] A. M. Wu,et al. Protection against Brucella abortus in mice with O-polysaccharide-specific monoclonal antibodies , 1986, Infection and immunity.
[19] B. L. Deyoe,et al. Experimentally induced Brucella abortus infection in pregnant goats. , 1986, American journal of veterinary research.
[20] P. Elzer,et al. Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. , 1989, Journal of immunology.
[21] L. G. Adams,et al. Capacity of passively administered antibody to prevent establishment of Brucella abortus infection in mice , 1989, Infection and immunity.
[22] B. L. Deyoe,et al. Protection of mice against Brucella abortus infection by inoculation with monoclonal antibodies recognizing Brucella O-antigen. , 1989, American journal of veterinary research.
[23] J. D. Colmenero Castillo,et al. Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis. , 1989, Chemotherapy.
[24] M. Miravitlles,et al. Treatment of Human Brucellosis with Doxycycline plus Rifampin or Doxycycline plus Streptomycin , 1992, Annals of Internal Medicine.
[25] R. Gerli,et al. Lymphocytes bearing the gamma delta T cell receptor in acute Brucella melitensis infection. , 1993, European journal of immunology.
[26] J. Montejo,et al. Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] J. Blasco,et al. Evaluation of vaccines and of antigen therapy in a mouse model for Brucella ovis. , 1993, Vaccine.
[28] R. Gerli,et al. Lymphocytes bearing the γδ T cell receptor in acute Brucella melitensis infection , 1993 .
[29] W. G. Miller,et al. Characteristics of a Brucella Species from a Bottlenose Dolphin (Tursiops Truncatus) , 1994, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.
[30] P. Elzer,et al. BALB/c mice infected with Brucella abortus express protracted polyclonal responses of both IgG2a and IgG3 isotypes. , 1994, Immunology letters.
[31] G. Splitter,et al. CD8+ Type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I‐ and class II‐deficient mice , 1995, European journal of immunology.
[32] E. M. Hoffmann,et al. Contradictory roles for antibody and complement in the interaction of Brucella abortus with its host. , 1995, Critical reviews in microbiology.
[33] C. Baldwin,et al. Interleukin-10 downregulates protective immunity to Brucella abortus , 1995, Infection and immunity.
[34] G. Splitter,et al. RecombinantBrucella abortusProteins That Induce Proliferation and Gamma-Interferon Secretion by CD4+T Cells fromBrucella-Vaccinated Mice and Delayed-Type Hypersensitivity in Sensitized Guinea Pigs , 1996 .
[35] G. Splitter,et al. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. , 1996, Vaccine.
[36] P. Thompson,et al. Brucella species infection in North Sea seal and cetacean populations , 1996, Veterinary Record.
[37] D. Fuller,et al. Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization , 1996 .
[38] Zhanqi Liu,et al. Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms , 1996, Infection and immunity.
[39] J. Dubuisson,et al. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode , 1997, Journal of virology.
[40] M. Palmer,et al. Effects of oral or intravenous inoculation with Brucella abortus strain RB51 vaccine in beagles. , 1997, American journal of veterinary research.
[41] G. Splitter,et al. Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. , 1997, Vaccine.
[42] R. Vemulapalli,et al. Cloning and Sequencing of yajC and secDHomologs of Brucella abortus and Demonstration of Immune Responses to YajC in Mice Vaccinated with B. abortus RB51 , 1998, Infection and Immunity.
[43] T. Ficht,et al. Transposon-Derived Brucella abortusRough Mutants Are Attenuated and Exhibit Reduced Intracellular Survival , 1998, Infection and Immunity.
[44] M. Castillejos,et al. Multivariate model for predicting relapse in human brucellosis. , 1998, The Journal of infection.
[45] C. Cheers,et al. Control of IL-12 and IFN-gamma production in response to live or dead bacteria by TNF and other factors. , 1998, Journal of immunology.
[46] R. Vemulapalli,et al. Vaccination with Live Escherichia coli ExpressingBrucella abortus Cu/Zn Superoxide Dismutase Protects Mice against Virulent B. abortus , 1999, Infection and Immunity.
[47] S. Henri,et al. Identification of a candidate vaccine peptide on the 37 kDa Schistosoma mansoni GAPDH. , 2000, Vaccine.
[48] J. Blasco,et al. In vitro markers and biological activity in mice of seed lot strains and commercial Brucella melitensis Rev 1 and Brucella abortus B19 vaccines. , 2000, Biologicals : journal of the International Association of Biological Standardization.
[49] E. Andrews,et al. Identification and partial characterisation of a new protective antigen of Brucella abortus. , 2000, Journal of medical microbiology.
[50] G. Schurig,et al. Humoral immune response of BALB/c mice to a vaccinia virus recombinant expressing Brucella abortus GroEL does not correlate with protection against a B. abortus challenge. , 2000, Veterinary microbiology.
[51] T. Ficht,et al. Identification of Genes Required for Chronic Persistence of Brucella abortus in Mice , 2000, Infection and Immunity.
[52] T. Hadfield,et al. Impaired Control of Brucella melitensisInfection in Rag1-Deficient Mice , 2000, Infection and Immunity.
[53] C. Baldwin,et al. Interferon‐γ is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice , 2001, Immunology.
[54] J. Letesson,et al. Protection of BALB/c Mice against Brucella abortus 544 Challenge by Vaccination with Bacterioferritin or P39 Recombinant Proteins with CpG Oligodeoxynucleotides as Adjuvant , 2001, Infection and Immunity.
[55] T. Hadfield,et al. Bacteriologic and histologic features in mice after intranasal inoculation of Brucella melitensis. , 2001, American journal of veterinary research.
[56] M. Bronze,et al. Bacterial Pathogens as Biological Weapons and Agents of Bioterrorism , 2002, The American journal of the medical sciences.
[57] D. Fuller,et al. Particle-mediated DNA vaccination of mice, monkeys and men: looking beyond the dogma. , 2002, Current opinion in molecular therapeutics.
[58] V. DelVecchio,et al. Characterization of the caprine model for ruminant brucellosis. , 2002, Veterinary microbiology.
[59] V. Azevedo,et al. Molecular and immunological characterisation of recombinant Brucella abortus glyceraldehyde-3-phosphate-dehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin-12-expressing plasmid in a DNA vaccine formulation. , 2002, Journal of medical microbiology.
[60] V. Azevedo,et al. Induction of a th1-type of immune response but not protective immunity by intramuscular DNA immunisation with Brucella abortus GroEL heat-shock gene. , 2002, Journal of medical microbiology.
[61] J. Letesson,et al. Yersinia enterocolitica as a Vehicle for a Naked DNA Vaccine Encoding Brucella abortus Bacterioferritin or P39 Antigen , 2002, Infection and Immunity.
[62] J. Oliaro,et al. The innate immune response against Brucella in humans. , 2002, Veterinary microbiology.
[63] L. Capasso,et al. Bacteria in two-millennia-old cheese, and related epizoonoses in Roman populations. , 2002, The Journal of infection.
[64] G. Splitter,et al. Virulence Criteria for Brucella abortus Strains as Determined by Interferon Regulatory Factor 1-Deficient Mice , 2002, Infection and Immunity.
[65] M. Spitz,et al. A DNA Vaccine Encoding Lumazine Synthase from Brucella abortus Induces Protective Immunity in BALB/c Mice , 2002, Infection and Immunity.
[66] Mary S. Wu,et al. Induction of Mucosal Protection against Primary, Heterologous Simian Immunodeficiency Virus by a DNA Vaccine , 2002, Journal of Virology.
[67] Mice immune responses to Brucella abortus heat shock proteins. Use of baculovirus recombinant-expressing whole insect cells, purified Brucella abortus recombinant proteins, and a vaccinia virus recombinant as immunogens. , 2002, Veterinary microbiology.
[68] T. Ficht. Discovery of Brucella virulence mechanisms using mutational analysis. , 2002, Veterinary microbiology.
[69] K. Hamajima,et al. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. , 2003, Blood.
[70] G. Atkins,et al. Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[71] E. Andrews,et al. A DNA Vaccine Encoding Cu,Zn Superoxide Dismutase of Brucella abortus Induces Protective Immunity in BALB/c Mice , 2003, Infection and Immunity.
[72] F. Goldbaum,et al. Brucella Lumazine Synthase Elicits a Mixed Th1-Th2 Immune Response and Reduces Infection in Mice Challenged with Brucella abortus 544 Independently of the Adjuvant Formulation Used , 2003, Infection and Immunity.
[73] B. Wallace,et al. Laboratory-acquired Brucellosis , 2004, Emerging infectious diseases.
[74] D. Hoover,et al. Pathologic changes associated with brucellosis experimentally induced by aerosol exposure in rhesus macaques (Macaca mulatta). , 2004, American journal of veterinary research.
[75] Gustavo Moraga-Cid,et al. Intraspleen Delivery of a DNA Vaccine Coding for Superoxide Dismutase (SOD) of Brucella abortus Induces SOD-Specific CD4+ and CD8+ T Cells , 2004, Infection and Immunity.
[76] D. Montefiori,et al. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen , 2004, AIDS.
[77] I. Kakoma,et al. Evaluation of the Sprague-Dawley rat as a model for vertical transmission of Brucella abortus. , 2005, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.
[78] S. Rabot,et al. A Novel Mucosal Vaccine Based on Live Lactococci Expressing E7 Antigen and IL-12 Induces Systemic and Mucosal Immune Responses and Protects Mice against Human Papillomavirus Type 16-Induced Tumors , 2005, The Journal of Immunology.
[79] G. Donoso,et al. An RNA Vaccine Based on Recombinant Semliki Forest Virus Particles Expressing the Cu,Zn Superoxide Dismutase Protein of Brucella abortus Induces Protective Immunity in BALB/c Mice , 2005, Infection and Immunity.
[80] G. Splitter,et al. Unraveling Brucella Genomics and Pathogenesis in Immunocompromised IRF‐1−/− Mice , 2005, American journal of reproductive immunology.
[81] V. Lafont,et al. Vγ9Vδ2 T cells use a combination of mechanisms to limit the spread of the pathogenic bacteria Brucella , 2005 .
[82] S. Estein,et al. A DNA Vaccine Coding for the Brucella Outer Membrane Protein 31 Confers Protection against B. melitensis and B. ovis Infection by Eliciting a Specific Cytotoxic Response , 2005, Infection and Immunity.
[83] Tolerance of the human brucellosis vaccine and the intradermal reaction test for brucellosis , 1994, European Journal of Clinical Microbiology and Infectious Diseases.
[84] R. Vemulapalli,et al. Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein. , 2005, Veterinary microbiology.
[85] S. Estein,et al. Vaccination with the Recombinant Brucella Outer Membrane Protein 31 or a Derived 27-Amino-Acid Synthetic Peptide Elicits a CD4+ T Helper 1 Response That Protects against Brucella melitensis Infection , 2005, Infection and Immunity.
[86] H. Flick-Smith,et al. Human Immune Response to a Plague Vaccine Comprising Recombinant F1 and V Antigens , 2005, Infection and Immunity.
[87] Xinghong Yang,et al. Selection of Protective Epitopes for Brucella melitensis by DNA Vaccination , 2005, Infection and Immunity.
[88] R. Vemulapalli,et al. Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2. , 2006, Immunobiology.
[89] P. Li,et al. Protective Immunity Elicited by a Divalent DNA Vaccine Encoding Both the L7/L12 and Omp16 Genes of Brucella abortus in BALB/c Mice , 2006, Infection and Immunity.
[90] S. Perkins,et al. Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination. , 2006, Vaccine.
[91] J. Haynes,et al. Epidermal DNA vaccine for influenza is immunogenic in humans. , 2006, Vaccine.
[92] F. Goldbaum,et al. Brucella outer membrane protein Omp31 is a haemin-binding protein. , 2006, Microbes and infection.
[93] P. Li,et al. DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. , 2006, Chinese medical journal.
[94] E. Andrews,et al. Vaccination with Live Escherichia coli Expressing Brucella abortus Cu/Zn Superoxide‐Dismutase , 2006, Microbiology and immunology.
[95] Y. Le Loir,et al. Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis , 2006, Microbial cell factories.
[96] C. Seabury,et al. Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis. , 2006, Vaccine.
[97] Yi-jing Li,et al. [Progress on lactococcus lactis expressing heterologous antigens as live mucosal vaccines]. , 2006, Wei sheng wu xue bao = Acta microbiologica Sinica.
[98] H. Cai,et al. A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. , 2007, DNA and cell biology.
[99] D. Doolan,et al. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. , 2007, Immunology letters.
[100] Xinghong Yang,et al. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. , 2007, Vaccine.
[101] C. Mervis,et al. Rearrangements of the Williams–Beuren syndrome locus: molecular basis and implications for speech and language development , 2007, Expert Reviews in Molecular Medicine.
[102] B. Wren,et al. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. , 2007, Vaccine.
[103] D. Zelterman,et al. Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. , 2007, Vaccine.
[104] S. Estein,et al. Improved Immunogenicity of a Vaccination Regimen Combining a DNA Vaccine Encoding Brucella melitensis Outer Membrane Protein 31 (Omp31) and Recombinant Omp31 Boosting , 2007, Clinical and Vaccine Immunology.
[105] T. Ficht,et al. Aerosol Infection of BALB/c Mice with Brucella melitensis and Brucella abortus and Protective Efficacy against Aerosol Challenge , 2007, Infection and Immunity.
[106] S. Olsen,et al. An Aerosolized Brucella spp. Challenge Model for Laboratory Animals , 2007, Zoonoses and public health.
[107] M. A. Ansari,et al. Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. , 2007, Vaccine.
[108] M. Imperiale,et al. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[109] M. Delpino,et al. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. , 2007, Vaccine.
[110] D. Laplagne,et al. A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. , 2007, Vaccine.
[111] D. Laplagne,et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. , 2007, Vaccine.
[112] J. Gorvel,et al. Virulence factors in brucellosis: implications for aetiopathogenesis and treatment , 2007, Expert Reviews in Molecular Medicine.
[113] T. Ficht,et al. Immunization with a Single Dose of a Microencapsulated Brucella melitensis Mutant Enhances Protection against Wild-Type Challenge , 2008, Infection and Immunity.
[114] Sandra K. Martin,et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. , 2008, JAMA.
[115] Z. Hubálek,et al. Brucella microti sp. nov., isolated from the common vole Microtus arvalis. , 2008, International journal of systematic and evolutionary microbiology.
[116] E. Andrews,et al. Evaluation of Brucella abortus DNA and RNA vaccines expressing Cu-Zn superoxide dismutase (SOD) gene in cattle. , 2008, Veterinary microbiology.
[117] T. Ficht,et al. The Brucella abortus S19 ΔvjbR Live Vaccine Candidate Is Safer than S19 and Confers Protection against Wild-Type Challenge in BALB/c Mice When Delivered in a Sustained-Release Vehicle , 2008, Infection and Immunity.
[118] O. Zhirnov,et al. Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response. , 2008, Vaccine.
[119] S. Estein,et al. Immunization with Recombinant Brucella Species Outer Membrane Protein Omp16 or Omp19 in Adjuvant Induces Specific CD4+ and CD8+ T Cells as Well as Systemic and Oral Protection against Brucella abortus Infection , 2008, Infection and Immunity.
[120] S. Srivastava,et al. Escheriosomes entrapped DNA vaccine co-expressing Cu-Zn superoxide dismutase and IL-18 confers protection against Brucella abortus. , 2008, Microbes and infection.
[121] J. Al-Tawfiq. Therapeutic options for human brucellosis , 2008, Expert review of anti-infective therapy.
[122] H. Atkins,et al. Development and Characterization of Mouse Models of Infection with Aerosolized Brucella melitensis and Brucella suis , 2009, Clinical and Vaccine Immunology.
[123] P. Nathanielsz,et al. A novel Brucella isolate in association with two cases of stillbirth in non‐human primates – first report , 2009, Journal of medical primatology.
[124] G. Vergnaud,et al. Brucella inopinata sp. nov., isolated from a breast implant infection. , 2010, International journal of systematic and evolutionary microbiology.